This trial is active, not recruiting.

Conditions advanced malignancy, advanced solid tumors, cancer, oncology, oncology patients, tumors, glioblastoma, multiple myeloma
Treatment amg 232
Phase phase 1
Target MDM2
Sponsor Amgen
Start date December 2012
End date March 2017
Trial size 107 participants
Trial identifier NCT01723020, 20120106


First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
AMG 232 is an anti-cancer agent.
amg 232
Given an an oral tablet in escalating doses.

Primary Outcomes

time frame: 36 months

Secondary Outcomes

Objective Tumor Response
time frame: 36 months

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Men or women > 18 years old - Pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment, or which no standard therapy is available, or the subject refuses standard therapy or multiple myeloma - Willing to undergo pre-dose core needle tumor biopsies or bone marrow aspirate for subjects with multiple myeloma. - Ability to take oral medications and willing to record daily adherance to investigational product - Adequate hematological, renal, hepatic, and coagulation laboratory assessments Exclusion Criteria: - Active brain metastases - For solid tumor-History or presence of hematological malignancies unless curatively treated with no evidence of disease for greater than or equal to 5 years - Active infection requiring intravenous (IV) antibiotics - Anti-tumor therapy - Therapeutic or palliative radiation therapy within 30 days of starting treatment - Currently enrolled in another investigational device or drug study

Additional Information

Official title A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Description Study Design: This is an open-label, dose exploration study evaluating AMG 232 in subjects with advanced p53WT solid tumors or multiple myeloma. The study will be conducted in 2 parts: Part 1 - Dose Exploration (parts 1a, 1b and 1c) and Part 2 - Dose Expansion. Part 1a is aimed at evaluating the safety, tolerability, PK and PD of AMG 232 and determining the MTD of a 7-day once daily (QD) dosing schedule in subjects with advanced solid tumors using a practical continuous reassessment method (CRM). Part 1b will evaluate the safety and tolerability of 3-day QD dosing schedule (or alternate dosing schedule based upon emerging data) with a particular emphasis on evaluating the tolerability of daily doses equal to or higher than the part 1a MTD in subjects with solid tumors or multiple myeloma. Part 1c will evaluate the safety and tolerability of 7-day twice daily (BID) dosing schedule with daily cumulative doses equal to or higher than the part 1a MTD in subjects with solid tumors. The dose expansion part of the study (Part 2) can open once the MTD has been determined in Part 1a. Part 2, part 1b and part 1c can be explored in parallel. The dose expansion part will consist of up to 85 additional subjects with specific tumors harboring MDM2 amplification (liposarcoma [LPS], gliobastoma [ GBM ] and all other solid tumors) or potentially harboring MDM2 overexpression (ER+ metastatic breast cancer) and a group of subjects with multiple myeloma.
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Amgen.